Antimicrobial prescriptions and adherence to prudent use guidelines for selected canine diseases in Switzerland in 2016

Berénice Lutz,1 Claudia Lehner,1 Kira Schmitt,2 Barbara Willi,2 Gertraud Schüpbach,3 Meike Mevissen,4 Ruth Peter,5 Cedric Müntener,5 Hanspeter Naegeli,5 Simone Schuller5

ABSTRACT
Background Antimicrobial resistance is an increasing problem in human and veterinary medicine and is closely linked to the use of antimicrobials. The objective of this study was to describe antimicrobial prescriptions for selected canine diseases in Switzerland during 2016.

Methods Dogs presented to two university hospitals and 14 private practices for acute diarrhoea (AD; n=371), suspected or confirmed urinary tract infections (UTIs; n=245), respiratory tract infections (RTIs; n=274) or wound infections (WIs; n=175) were included. Clinical history, diagnostic work-up and antimicrobial prescription (class, dosage and duration) were retrospectively assessed. A justification score was applied to evaluate appropriateness of antimicrobial therapy based on available national and international consensus guidelines.

Results Antimicrobials were prescribed in 65 per cent of dogs with AD, 88 per cent with UTI, 62 per cent with RTI and 90 per cent with WI. The most prescribed antimicrobial classes (monotherapy or combination therapy) were potentiated aminopenicillins (59 per cent), nitroimidazoles (22 per cent), non-potentiated aminopenicillins (16 per cent) and fluoroquinolones (13 per cent). Overall, 38 per cent (95 per cent CI 0.35 to 0.41) of the prescriptions were in accordance with consensus guidelines. In dogs with AD, antimicrobial therapy was associated with the presence of haemorrhagic diarrhoea (P<0.05) and complied in 32 per cent with consensus guidelines, which recommend antimicrobial treatment only when sepsis is suspected. A bacterial aetiology was confirmed via culture and/or sediment examination in 36 per cent of dogs with suspected UTI.

Conclusions Overall, adherence to consensus guidelines was poor both at university hospitals and private practices. Antimicrobial stewardship measures are therefore needed to improve prudent use.

INTRODUCTION
Antimicrobials are vital to modern medicine, and antimicrobial resistance is a global, urgent threat to human and animal health. The development of antimicrobial resistance is unambiguously linked to exposure of bacteria to antimicrobials.1 Dogs and cats are considered family members in many households and benefit from advanced medical care, which often includes hospitalisation and treatments with broad-acting antimicrobials, many of them being of critical importance to human medicine. The selection pressure put on bacterial populations via the administration of antimicrobials favours the selection of multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus pseudintermedius and extended-spectrum beta-lactamase producing Escherichia coli.2–5 Small animal medicine therefore likely plays a significant role in the selection and dissemination of MDROs. To foster the prudent use of antimicrobials, guidelines have been created in both human and veterinary medicine.6–9

Antimicrobial prescribing habits by small animal veterinarians have been reported from a number of countries including the USA,10 Australia,11 Belgium,12 UK,13 Finland,14 Denmark15 and Italy.16 Such studies are either designed as surveys using fictional case scenarios,11–13,15,16 or based on data extracted from pharmacy or patient records.14,17–23 Patterns of antimicrobial use for selected diseases in cats in Switzerland have recently been published.24 The results of these studies indicate that overprescription of antimicrobials including critically important antimicrobials and non-adherence to guidelines is common in small animal medicine but varies considerably between countries. In Europe, a north-to-south and a west-to-east gradient with lower percentages of resistant bacterial isolates reported in the north and west of Europe have been described.25 This phenomenon is partly linked to the existence and level of implementation of national antimicrobial stewardship strategies.7,8 In order to achieve
the highest possible impact of prudent use guidelines, current prescribing behaviours as well as the regional availability of specific antibiotics need to be taken into consideration. It is therefore crucial to perform studies at a national as well as international level.

In 2015, the Swiss National Strategy on Antibiotic resistance was passed by the federal council. As part of its implementation, an online tool (AntibioticScout.ch) assisting veterinarians in the selection of prudent empirical antimicrobial therapy was created. This tool became available to veterinarians in December 2016.26 27

The aim of this study was to assess antimicrobial use in small animal medicine in Switzerland in 2016, before introduction of the antimicrobial stewardship tool AntibioticScout.ch. Four conditions in dogs for which antimicrobials are frequently prescribed, including acute diarrhoea (AD), urinary tract infections (UTI), respiratory tract infections (RTI) and wound infections (WI), were selected to describe prescription habits of veterinarians and their accordance with national and international prudent use recommendations.7–9 28

**MATERIALS AND METHODS**

**Study design**

The study was designed as a retrospective multicentre study involving two university teaching hospitals with annual caseloads of 6000 and 12,000 cases, respectively, and 14 private practices across Switzerland ranging from one-vet mixed practices to middle-sized small animal clinics. It also included one very large private clinic with over 80,000 cases per year. Antimicrobial prescriptions were assessed for selected diseases in both dogs and cats using the same study design. The results in cats have recently been published.24

**Data collection**

Electronic medical records were screened via full-text searches for eligible patients using predefined search terms (table 1). Dogs with AD, proven or suspected UTI, proven or suspected RTI and WI were included if they met the inclusion criteria outlined in table 1. Data collection was performed as previously described.24 Briefly, private practices using either OblonData (Amacker & Partner Informatik AG, Switzerland) or Diana SUISSE (Diana Software AG, Switzerland) practice management software were included.

The sample size for private practices was calculated to estimate the prevalence of treatment according to guidelines, corresponding to a justification score of 1 (JS-1) with a precision of ±8 per cent, assuming a prevalence of 50 per cent, a confidence level of 95 per cent and a population size of 550,000 registered dogs in Switzerland.29 The sample size of 151 cases per indication, which was determined with the Epitools online calculator (https://epitools.ausvet.io/site/samplesize), was rounded up to a target sample size of 160. To avoid over-representation of large practices, we limited the number of cases per practice to 16 (10 per cent of the target sample size), which were randomly selected via the sampling function in Excel. For the university clinics, all available cases were

| Table 1 | Inclusion and exclusion criteria and search terms for the surveyed indications |
|---------|---------------------------------------------------------------|
| **Indication**                              | **Included**                               | **Excluded**                               | **Search terms**                      |
| Acute diarrhoea                          | Diarrhoea <3 weeks.                              | Diarrhoea >3 weeks or relapsing.           | Diarrhoea, colitis, duodenitis, enteritis, ileitis, gastritis, AHDS, haemorrhagic gastroenteritis and Giardia, watery stools. |
|                                               | Acute haemorrhagic diarrhoea syndrome (AHDS).   | Diarrhoea related to drug administration or another extradigestive disease. | |
|                                               | Parasitic diarrhoea.                             | Diarrhoea that appeared during hospitalisation. | |
|                                               | Non-specific diarrhoea.                         | Paroviroisis.                             | |
| Urinary tract infection                  | Suspicion or diagnosis of bacterial cystitis.   | Glomerulonephritis.                       | Urinary tract infection, dysuria, difficult urination, stranguria, haematuria, bloody urine, blood in urine, polyuria, pollakiuria, pyelonephritis, inflammation of the bladder, cystitis, bladder and urinanalysis. |
|                                               | Suspicion or diagnosis of pyelonephritis.       | Leptospirosis.                           | |
|                                               |                                                | Urolithiasis without signs of bacteriuria. | |
| Respiratory tract infection              | Aspiration pneumonia.                          | Nasal infections.                        | Respiratory tract infection, respiratory tract disease, cough, tracheitis, tracheobronchitis, pneumonia, inflammation of the lungs, bronchitis, bronchopneumonia, kennel cough, distemper, influenza, adenovirus, dyspnoea and tachypnoea. |
|                                               | Pneumonia (bacterial, viral and unknown).       | Fungal infections.                       | |
|                                               | Bronchitis.                                    | Neoplasia of the respiratory tract.       | |
|                                               | Kennel cough.                                  | Lung worms.                              | |
| Wound infection                           | Bite wound.                                    | Anal gland abscess.                      | Wound infection, abscess, purulent wound and bite. |
|                                               | Abscess.                                       | Dental abscess.                          | |
|                                               |                                                | Abscess due to a foreign body.            | |
|                                               |                                                | Hotspot.                                 | |
included in order to get close to the target sample size of 160 cases per indication.

Due to the relatively rare occurrence of uncomplicated abscesses and WI at university teaching hospitals, this indication was only assessed in cases from private practices. Signalment, vaccination status, clinical history, clinical examination, treatment with antimicrobials within seven days before presentation, diagnostic work-up, comorbidities as well as hospitalisation length were recorded in addition to parameters relating to antimicrobial therapy including class, dosage, frequency of application and duration of therapy. In dogs with several problems, antimicrobial prescriptions were not recorded, if it was clear that they were given to treat coinfection of a different organ system.

Animals, which were presented again for the same problem, were only included once.

Definitions
Minimal diagnostic work-up was defined as a complete blood count (CBC) for AD, urinary sediment examination for UTI and a CBC and at least one thoracic radiographic view for RTI.

Bacteriuria was defined as the presence of bacteria in sediment analysis or in bacterial culture from an aseptically collected urine sample (cystocentesis). Complicated UTI was defined according to previous guidelines as infection in the presence of anatomical or functional changes or disorders of the immune system, recurrent UTI (three times per year or more) and UTI in non-castrated males. These guidelines, which were published in 2011, have since been substantially revised. The revised guidelines have been published in 2019.

Sepsis criteria were considered fulfilled if dogs showed lethargy in addition to at least one of the following criteria proposed by Hauptman and others: body temperature >39.4°C, heart rate >140/min, white blood cell (WBC) <4 or >25×10⁹/l and banded neutrophils >1.5×10⁹/l. Cases of RTI were categorised as severe if the dogs fulfilled above-mentioned sepsis criteria in addition to signs of pulmonary involvement, either by auscultation (crackles) or on at least one lateral thoracic radiograph. A more detailed severity score could not be applied because relevant data were commonly missing from the medical records. For the same reason, the severity of disease was not assessed in the remaining three indications.

In accordance with WHO guidelines, highest priority critically important antimicrobials (HPCIAs) were defined as third-generation or fourth-generation cephalosporins, quinolones, macrolides, ketolides, glycopeptides and polymyxins. Combination therapy was defined as the prescription of two or more antibiotic classes at the same time.

Justification score
Antimicrobial prescriptions were compared with the recommendations summarised in table 2, which were based on existing consensus national and international guidelines. A previously published justification score (JS-1 to JS-4) was used with modifications to evaluate the appropriateness of the prescription in all cases where sufficient clinical information was available (table 3).

For the duration and dosage, ±1 day and up to ±20 per cent deviations were accepted.

Statistical analysis
Data were evaluated using a commercial statistical software package (NCSS11 Statistical Software (2016) ncss.com/software/ncss). Descriptive statistics were used for patient characteristics including sex, age and prescribed antimicrobials (table 4). Shapiro-Wilk testing revealed non-normal distribution for age, weight and duration of treatment (in each category), which were therefore reported as median and IQR. Patient characteristics, antimicrobial pretreatments, differences in diagnostic work-up, antibiotic classes, the use of HPCIAs and duration of therapy were recorded and compared between dogs presented to university hospitals and private practices using the chi-squared test or Fisher’s exact test when the expected value in a cell was <5 for categorical and the Mann-Whitney test for continuous variables. The Bonferroni method was applied to correct the significance levels for multiple comparisons.

Risk factors for the unfavourable JS-3 and JS-4 and for the prescription of HPCIAs were identified using univariate logistic regression analysis. The following potential risk factors were assessed: presence of haemorrhagic diarrhoea, presence of leucopenia or leukocytosis and the presence of a left-shift for AD; complicated UTI, non-castrated male status and urinary catheterisation for UTI; and duration of clinical signs ≤7 days, lacking or not up to date vaccinations, lack of minimal work-up, hospitalisation and presence of a left shift for RTI. Finally, for WI, age less than three years, hospitalisation, local treatment of the wound and presence of a left shift were examined. All other associations were studied using the chi-squared test. Multivariable logistic regression analysis was attempted, but due to the low number of dogs in each category for which detailed clinical information was available, no relevant associations could be identified. Results are reported as per cent with 95 per cent CIs where appropriate or as ORs with 95 per cent CIs. Significance was set at P<0.05 for all tests apart from the post hoc multiple comparisons.

RESULTS
Case characteristics
A total of 1065 dogs were included in the study, 343 of which were presented at university hospitals and 722 at private practices. Case characteristics are shown in table 4. Age and sex were not significantly different between the dogs seen at university hospitals and those seen at private practices. Dogs presented to a university hospital were significantly more likely to be pretreated with antimicrobials (24 per cent, 95 per cent CI 0.19 per
### Table 2  Criteria used to judge appropriate use of antimicrobials based on national and international recommendations

| Indication                        | Comment                                                                 | Antimicrobial                  | Dosage (mg/kg) | Application frequency | Treatment duration (days) |
|----------------------------------|--------------------------------------------------------------------------|--------------------------------|----------------|-----------------------|---------------------------|
| **Acute diarrhoea**              | Antimicrobial therapy NOT indicated unless clinical suspicion of sepsis based on clinical and laboratory data.⁷–⁹ | Ampicillin                    | 20             | Twice daily/three times a day | 5–7                       |
|                                  |                                                                          | Amoxicillin                   | 11–15          | Twice daily/three times a day | 5–7                       |
|                                  |                                                                          | Amoxicillin/clavulanic acid   | 12.5–20        | Twice daily/three times a day | 5–7                       |
|                                  |                                                                          | Ampicillin/sulbactam‡         | 30             | Twice daily/three times a day | 5–7                       |
|                                  | If suspicion of sepsis* and no improvement with initial therapy after two to three days, antimicrobial spectrum may be extended by adding.⁷–⁹ | Enrofloxacin OR               | 10–20          | Once daily             | 5–7                       |
|                                  |                                                                          | Marbofloxacin AND/OR          | 2              | Once daily             | 5–7                       |
|                                  |                                                                          | Metronidazole                 | 15             | Twice daily            | 5–7                       |
| **UTIs**                         | According to 2011 guidelines, complicated UTIs are defined as infections caused by anatomical or functional changes or disorders of the immune system, recurrent UTI (three times per year or more) or UTI in non-castrated male.²⁸ | Ampicillin†                   | 20             | Twice daily/three times a day | 5–7                       |
|                                  | **Sporadic (uncomplicated) UTI**                                         | Amoxicillin                   | 11–15          | Twice daily/three times a day | 5–7                       |
|                                  |                                                                          | Ampicillin†                   | 20             | Twice daily/three times a day | 5–7                       |
|                                  | **Complicated UTI**                                                      | Amoxicillin                   | 11–15          | Twice daily/three times a day | 5–28                      |
|                                  |                                                                          | Amoxicillin/clavulanic acid   | 12.5–20        | Twice daily/three times a day | 5–28                      |
|                                  |                                                                          | Ampicillin†                   | 20             | Twice daily/three times a day | 5–28                      |
|                                  |                                                                          | Ampicillin/sulbactam‡         | 30             | Twice daily/three times a day | 5–28                      |
|                                  |                                                                          | Trimethoprim/sulfadiazin      | 15             | Twice daily            | 5–28                      |
|                                  |                                                                          | Trimethoprim/sulfamethoxazole | 15             | Twice daily            | 5–28                      |
| **Non-castrated male dogs**      |                                                                          | **Enrofloxacin**              | 10–20          | Once daily             | 5–42                      |
|                                  |                                                                          | Marbofloxacin                 | 2              | Twice daily            | 5–42                      |
|                                  |                                                                          | Trimethoprim/sulfadiazin      | 15             | Twice daily            | 5–28                      |
|                                  |                                                                          | Trimethoprim/sulfamethoxazole | 15             | Twice daily            | 5–28                      |
| **Respiratory tract infections** | Aspiration pneumonia or bacterial bronchopneumonia.⁷–⁹                   | **Mild to moderate disease**  |                |                       |                           |
|                                  |                                                                          | Doxycycline                   | 10             | Once daily             | Treatment 1 week beyond resolution of clinical/radiographic signs |
|                                  |                                                                          | Amoxicillin/clavulanic acid   | 12.5–20        | Twice daily/three times a day |                           |
|                                  |                                                                          | Ampicillin/sulbactam‡         | 30             | Twice daily/three times a day |                           |
| **Severe cases**                 |                                                                          | Amoxicillin/clavulanic acid OR| 12.5–20        | Twice daily/three times a day |                           |
|                                  |                                                                          | Ampicillin/sulbactam‡         | 30             | Twice daily/three times a day |                           |
|                                  |                                                                          | **AND**                       |                |                       |                           |
|                                  |                                                                          | Enrofloxacin OR               | 10–20          | Once daily             | 5–14                      |
|                                  |                                                                          | Marbofloxacin                 | 2              | Once daily             |                           |
|                                  |                                                                          | Doxycycline                   | 10             | Once daily             |                           |

Kennel cough: antimicrobial therapy only indicated if: poor general condition, rectal T>39.4°C or signs of lower airway involvement.⁷–⁹

Continued
cent to 0.28 per cent vs 2 per cent, 95 per cent CI 0.01 per cent to 0.04 per cent; P<0.001) and were significantly more frequently hospitalised (250/343; 73 per cent, 95 per cent CI 0.68 per cent to 0.78 per cent) compared with private practice (29/722; 4 per cent, 95 per cent CI 0.03 per cent to 0.06 per cent; P<0.001).

**Antimicrobial prescription overall**
In total, 786 (74 per cent) dogs received antimicrobials either as monotherapy (94 per cent) or combination therapy (6 per cent). The most used antimicrobials were potentiated aminopenicillins (59 per cent), followed by nitroimidazoles (22 per cent), non-potentiated aminopenicillins (16 per cent), fluoroquinolones (13 per cent), tetracyclines (5 per cent), first-generation (4 per cent) and third-generation cephalosporins (2 per cent). The proportion of dogs receiving combination therapy was significantly higher at university hospitals (34/343; 15 per cent, 95 per cent CI 0.07 per cent to 0.14) compared with private practices (13/520; 3 per cent, 95 per cent CI 0.07 per cent to 0.17) (P<0.001). There was no difference in the frequency of prescription of HPCIAs between university hospitals and private practices. Non-potentiated aminopenicillins were prescribed significantly more commonly in private practices (16 per cent, 95 per cent CI 0.14 per cent to 0.19 per cent) compared with university hospitals (3 per cent, 95 per cent CI 0.01 per cent to 0.04 per cent; P<0.001).

At university hospitals, a significantly higher proportion of prescriptions were in complete accordance (JS-1 48 per cent, 95 per cent CI 0.42 per cent to 0.53 per cent vs 34 per cent, 95 per cent CI 0.30 per cent to 0.37 per cent; P<0.001) or complete discordance (JS-4 35 per cent, 95 per cent CI 0.30 per cent to 0.40 per cent vs 28 per cent, 95 per cent CI 0.25 per cent to 0.31 per cent; P=0.02) with consensus guidelines compared with private practices. A significantly higher proportion of dogs at university hospitals was treated with an antimicrobial class not recommended in guidelines compared with private practice (JS-3 13 per cent, 95 per cent CI 0.09 per cent to 0.17 per cent vs 5 per cent, 95 per cent CI 0.04 per cent to 0.07 per cent; P<0.001). The proportions of dogs receiving an incorrect dosage or treatment duration (JS-2) was not significantly different between university hospitals and private practices (3 per cent, 95 per cent CI 0.01 per cent to 0.05 per cent vs 4 per cent, 95 per cent CI 0.03 per cent to 0.06 per cent; P=0.3).

No differences were found between the two university hospitals regarding the prescription of HPCIAs (P=0.3), of fluoroquinolones (P=0.2) or the use of combination therapy (P=0.5). Moreover, there was no significant difference in the number of cases in agreement (P=0.5) or disagreement (P=0.6) with the guidelines. The only significant difference between the two university hospitals was in the number of hospitalised patients (86 per cent, 95 per cent CI 0.79 per cent to 0.92 per cent vs 65 per cent, 95 per cent CI 0.58 per cent to 0.71 per cent; P<0.001).

**Antimicrobial prescriptions for AD**
Numbers and proportions of diagnostic procedures, antimicrobial prescriptions and justification scores for dogs with AD are shown in table 5.
| Parameter             | Acute diarrhoea | Urinary tract infections | Respiratory tract infections | Wound infections |
|-----------------------|-----------------|--------------------------|-----------------------------|------------------|
|                      | University hospitals | Private practices | P value* | University hospitals | Private practices | P value* | University hospitals | Private practices | P value* | Private practices |
| **Total**             | 165             | 206                      |          | 70                | 175              |          | 108                | 166              |          | 175              |
| **Sex**               |                 |                          |          |                   |                  |          |                    |                  |          |                  |
| Female, n (%)         | 74 (45)         | 99 (48)                  | 0.4      | 39 (56)           | 112 (64)         | 0.2      | 56 (52)            | 73 (44)          | 0.3      | 91 (52)           |
| Male, n (%)           | 91 (55)         | 102 (50)                 |          | 31 (44)           | 61 (35)          |          | 52 (48)            | 91 (55)          |          | 81 (46)           |
| Unknown, n (%)        | 0               | 5 (2)                    |          | 0                 | 2 (1)            |          | 0                  | 2 (1)            |          | 3 (2)             |
| **Age (years), median (IQR)** | 5 (2–8)           | 6 (1–9)                  | 0.5      | 10 (6–12)         | 8 (3.3–10.8)     | 0.02     | 6 (2–11)           | 7 (2–11)         | 0.9      | 6 (3–9.5)         |
| **Weight (kg), median (IQR)** | 10 (8–13)          | 13 (10–17)               | 0.03     | 18 (13–23)        | 21 (16–25)       | **<0.001** | 14 (9–19)          | 11 (9–17)        | 0.8      | 21 (11–28)        |
| **Breed**             |                 |                          | 0.2      |                   |                  |          |                    |                  | 0.07     |                  |
| Purebred, n (%)       | 140 (85)        | 165 (80)                 |          | 58 (83)           | 136 (76)         |          | 93 (86)            | 133 (80)         |          | 133 (76)          |
| Mixed breed, n (%)    | 22 (13)         | 38 (18)                  |          | 12 (17)           | 35 (20)          |          | 11 (10)            | 31 (19)          |          | 40 (23)           |
| Unknown, n (%)        | 3 (2)           | 3 (2)                    |          | 0                 | 4 (3)            |          | 4 (4)              | 2 (1)            |          | 2 (1)             |

*Statistically significant P values after Bonferroni correction (P<0.02) are written in bold characters.
Table 5  Diagnostic work-up and antibiotic prescriptions in 371 cases of canine acute diarrhoea cases presented to university hospitals or private practices

| Parameter | University hospitals | Private practices | P value* |
|-----------|----------------------|-------------------|----------|
| Total number of cases | 165 | 206 |          |
| Minimal diagnostic work-up, n (%)† | | | <0.001 |
| Yes | 131 (79) | 12 (6) | |
| No | 34 (20) | 194 (94) | |
| Sepsis criteria fulfilled, n (%)‡ | | | 0.08 |
| Yes | 34 (21) | 21 (10) | |
| No | 129 (78) | 134 (65) | |
| Unknown | 2 (1) | 51 (25) | |
| Haemorrhagic diarrhoea, n (%) | | | <0.001 |
| Yes | 101 (61) | 52 (25) | |
| No | 64 (39) | 132 (64) | |
| Unknown | 0 (0) | 22 (11) | |
| Hospitalisation, n (%) | | | <0.001 |
| Yes | 141 (85) | 9 (4) | |
| No | 24 (15) | 197 (96) | |
| Pretreated, n (%) | | | <0.001 |
| Yes | 24 (15) | 0 (0) | |
| No | 138 (84) | 194 (94) | |
| Unknown | 3 (1) | 12 (6) | |
| Antibiotic therapy, n (%) | | | 0.08 |
| Yes | 116 (70) | 127 (62) | |
| No | 55 (34) | 89 (42) | |
| Unknown | 0 (0) | 12 (6) | |
| Antibiotic classes, n (%) | | | <0.001 |
| Potentiated aminopenicillins | 55 (47) | 13 (10) | |
| Nitroimidazole | 74 (64) | 100 (79) | 0.5 |
| Non-potentiated aminopenicillins | 0 (0) | 9 (6) | 0.007 |
| Third-generation cephalosporins | 0 (0) | 3 (2) | 0.1 |
| Tetracyclines | 0 (0) | 3 (2) | 0.1 |
| Fluoroquinolones | 3 (3) | 15 (12) | 0.01 |
| Combination therapy, n (%) | | | 0.1 |
| Yes | 11 (9) | 6 (5) | |
| No | 105 (91) | 121 (95) | |
| HPCIAs, n (%)§ | | | 0.004 |
| Yes | 3 (3) | 18 (14) | |
| No | 113 (97) | 109 (86) | |
| Duration of therapy (days) | | | <0.001 |
| Median (IQR) | 8 (7–9) | 6 (5–7) | |
| Justification score, n (%) | | | 0.01 |
| 1 | 57 (35) | 62 (30) | 0.4 |
| 2 | 5 (3) | 0 (0) | | |

Table 5  Continued

| Parameter | University hospitals | Private practices | P value* |
|-----------|----------------------|-------------------|----------|
| 3 | 15 (9) | 3 (1) | <0.001 |
| 4 | 88 (53) | 102 (50) | 0.5 |
| Judgement not possible | 1 (0.6) | 39 (19) | |

*Statistically significant P values after Bonferroni correction are written in bold characters.
†Minimal work-up is CBC.
‡Criteria fulfilled if lethargic and at least one of the following: body temperature >39.4°C, heart rate >140/min, WBC <4 or >25×10⁹/l and band neutrophils >1.5×10⁹/l.
§HPCIA: highest priority critically important antimicrobials include third-generation or higher generation cephalosporins, quinolones, macrolides, ketolides, glycopeptides and polymyxins.

Of the 371 dogs presented for AD, 243 (65 per cent) received antimicrobial therapy with the following classes: nitroimidazoles (72 per cent), potentiated aminopenicillins (28 per cent), fluoroquinolones (7 per cent), non-potentiated aminopenicillins (4 per cent), third-generation cephalosporins (1 per cent) and tetracyclines (1 per cent). Combination therapy was prescribed in 7 per cent of the cases and was associated with the presence of sepsis criteria. Thirty-one twenty-one dogs (8 per cent) received at least one HPCIA. The use of HPCIA was not associated with the presence of sepsis criteria. The duration of the treatment was significantly longer at university hospitals compared with private practices.

A total of 143 dogs (39 per cent) underwent minimal diagnostic work-up (CBC) and 84 dogs (23 per cent) had a coprological examination performed. Giardia species was detected in 10/84 dogs and 7 of them received metronidazole.

Dogs presenting at university hospitals had significantly more haemorrhagic diarrhoea than those presenting at private practices (P<0.001). The presence of haemorrhagic diarrhoea was significantly associated with the use of antibiotics (P<0.001) and hospitalisation (P<0.001) but not with the presence of sepsis criteria (P=0.08). Univariate logistic regression analysis also showed that the odds for an incorrect utilisation of antimicrobials (JS-4) was 2.26 times higher in dogs with haemorrhagic diarrhoea (95 per cent CI 1.46 to 3.51; P<0.001).

Subgroup analysis of 55 dogs for which criteria of sepsis were fulfilled showed no significant difference regarding the overall antimicrobial prescription rate (P=0.1) nor the prescription of HPCIA (P=0.05) between university hospitals and private practices. However, there were significantly more cases in total disagreement with the guidelines at private practices (62 per cent) than at university hospitals (9 per cent; P<0.001).

When looking at the subgroup of 153 dogs with haemorrhagic diarrhoea, there was no significant difference between university hospitals and private practices with regards to the overall antimicrobial prescription rate
(P=0.6) and the prescription of HPCIs (P=0.08) as well the number of prescriptions in complete agreement (P=0.9) or complete disagreement (P=0.3) with consensus guidelines.

When looking at the subgroup of 160 dogs with AD that were hospitalised, there was no statistical difference between university hospitals and private practices regarding the overall antimicrobial prescription rate. However, HPCIs were more frequently used at private practices (16 per cent) than at university hospitals (2 per cent, P=0.003). A significantly higher proportion of cases was judged in total agreement (33 per cent vs 5 per cent; P=0.01) and a significantly lower proportion in complete disagreement (53 per cent vs 84 per cent; P=0.01) with guidelines at university hospitals than at private practices.

Agreement with consensus guidelines could be evaluated in 89 per cent (331/371) of dogs with AD. In these dogs, treatment was in total compliance with the consensus guidelines (JS-1) in 26 per cent of the cases and in total disagreement in 57 per cent of dogs (JS-4). For 18 (5 per cent) cases, the chosen antimicrobial class was not in agreement with the consensus guidelines (JS-3). In the majority of these cases (17/18), metronidazole was used instead of or in combination with the recommended potentiated aminopenicillins. The dogs with a JS-4 score were either treated when not needed (187/190; 98 per cent) or not treated when needed (3/190; 2 per cent).

### Antimicrobial prescription for UTI

Numbers and proportions of diagnostic procedures, antimicrobial prescriptions and justification scores for UTI are shown in table 6. Antimicrobials were prescribed in 215/245 dogs (88 per cent) with suspected or proven UTI. The following antimicrobials were prescribed as either monotherapy (98 per cent) or combination therapy (2 per cent): potentiated aminopenicillins (61 per cent), fluoroquinolones (22 per cent), non-potentiated aminopenicillins (11 per cent), first-generation cephalosporins (5 per cent), third-generation cephalosporins (1 per cent), lincosamides (0.8 per cent), amphenicols (0.4 per cent) and potentiated sulfonamides (0.4 per cent). All five dogs receiving combination therapy had urinary culture and antimicrobial susceptibility testing performed, demonstrating infection with MDROs in three and the presence of two different bacteria with different resistance profiles in two dogs.

The most frequently employed HPCIs were fluoroquinolones, and their use was not associated with a non-castrated male status (P=0.3). There was a borderline association between the presence of MDROs in urine and the use of HPCIs (P=0.06).

Diagnostic work-up (microscopic sediment analysis or culture) was significantly more commonly performed at university hospitals compared with private practices. Of all dogs receiving antimicrobials, 85 (40 per cent) had a confirmed bacterial aetiology.

In 50 per cent of the total cases, a justification score could not be attributed because of a lack of data and/or

### Table 6 Diagnostic work-up and antibiotic prescriptions in 245 dogs with suspected UTIs presented to university hospitals or private practices

| Parameter                                             | University hospital | Private practice | P value* |
|-------------------------------------------------------|---------------------|-----------------|----------|
| Number of cases                                       | 70                  | 175             |          |
| Microscopic sediment analysis, n (%)                  | Yes                 | 59 (84)         | <0.001   |
|                                                       | No                  | 11 (16)         |          |
| Bacterial culture, n (%)                              | Yes                 | 67 (96)         | <0.001   |
|                                                       | No                  | 3 (4)           |          |
| UTI considered complicated, n (%)                     | Yes                 | 48 (69)         | <0.001   |
|                                                       | No                  | 40 (56)         |          |
| Bacteriuria, n (%)†‡                                   | Confirmed           | 62 (88)         | <0.001   |
|                                                       | Excluded            | 7 (10)          |          |
|                                                       | No enough data to confirm or exclude bacterial aetiology | 1 (2) | 126 (72) |          |
| Hospitalisation, n (%)                                | Yes                 | 40 (56)         | <0.001   |
|                                                       | No                  | 30 (44)         |          |
| Pretreated, n (%)                                     | Yes                 | 14 (20)         | <0.001   |
|                                                       | No                  | 54 (77)         |          |
| Unknown                                               | Yes                 | 2 (3)           |          |
|                                                       | No                  | 2 (3)           |          |
| Antibiotic therapy                                    | Yes                 | 68 (97)         |          |
|                                                       | No                  | 2 (3)           |          |
| Antibiotic classes, n (%)                             | Potentiated aminopenicillins | 53 (78) | 97 (65) | 0.07 |
|                                                       | Fluoroquinolones    | 12 (17)         | 43 (29) | 0.07 |
|                                                       | Non-potentiated aminopenicillins | 5 (7) | 22 (15) | 0.2 |
|                                                       | First-generation cephalosporins | 2 (3) | 11 (7) | 0.2 |
|                                                       | Third-generation cephalosporins | 0 (0) | 3 (2) | 0.2 |
|                                                       | Lincosamide         | 2 (3)           | 0 (0)   | 0.02 |
|                                                       | Amphenicols         | 1 (1)           | 0 (0)   | 0.1  |
|                                                       | Potentiated sulfonamides | 1 (1) | 0 (0) | 0.1 |
| Combination therapy, n (%)                            | Yes                 | 5 (7)           | <0.001   |
|                                                       | No                  | 63 (93)         |        |
| Duration of therapy (days)                            | Median (IQR)        | 18 (10–27)      | <0.001   |

Continued
diagnostic work-up. Of all dogs for which a justification score could be given, complete accordance to the guidelines (JS-1) was observed in 49 dogs (20 per cent) and significantly more often at university hospitals compared with private practices (54 per cent vs 6 per cent; P<0.001). In 24 per cent of the dogs an inappropriate antimicrobial was prescribed (JS-3). In most of the cases, potentiated aminopenicillins were chosen as first-line treatment instead of non-potentiated aminopenicillins. The dogs with a JS-4 score were either treated when not needed (37/39; 95 per cent) or not treated when needed (2/39; 5 per cent).

**Antimicrobial prescription for RTI**

Numbers and proportions of diagnostic procedures, antimicrobial prescriptions and justification scores for RTI are shown in table 7. Of the 274 dogs, which were treated for suspected or confirmed RTI, 171 (62 per cent) received monotherapy or combination antimicrobial therapy of the following classes: potentiated aminopenicillins (43 per cent), tetracyclines (14 per cent), non-potentiated aminopenicillins (12 per cent), fluoroquinolones (10 per cent), first-generation (1 per cent) and third-generation cephalosporins (1 per cent). The use of HPCIA and the prescription of combination therapies were significantly more frequent at university hospitals (P<0.001). The use of combination therapy was not associated with cases categorised as severe (P=0.07).

Minimal work-up (CBC and thoracic radiographs) was more commonly performed at university hospitals (69 per cent vs 0.9 per cent; P<0.001). A diagnosis of aspiration pneumonia was made in 42 dogs (15 per cent) and 28 (10 per cent) dogs were diagnosed with kennel cough. In 13 dogs (5 per cent), a diagnosis of bronchitis resulted from radiography and also sometimes endoscopy, 3 dogs

---

**Table 6** Continued

| Parameter | University hospital | Private practice | P value* |
|-----------|---------------------|-----------------|----------|
| Justification score, n (%) |                      |                 |          |
| 1 | 38 (54) | 11 (6) | <0.001 |
| 2 | 4 (6) | 1 (0.5) | 0.01 |
| 3 | 13 (19) | 17 (10) | 0.06 |
| 4 | 14 (20) | 25 (14) | 0.3 |
| Judgement not possible | 1 (1) | 121 (69) |          |

*Statistically significant P values after Bonferroni correction are written in bold characters.

†Complicated UTI defined according to previous guidelines as infections in the presence of anatomical or functional changes or disorders of the immune system, recurrent UTI (three times per year or more) and UTI in non-castrated males.28

‡Defined as either positive microscopic sediment analysis or positive bacterial culture.

§HPCIA: highest priority critically important antimicrobials include third-generation or higher generation cephalosporins, quinolones, macrolides, ketolides, glycopeptides and polymyxins.

UTI, urinary tract infection.

---

**Table 7** Diagnostic work-up and antibiotic prescriptions in 274 dogs with respiratory tract infections presented to university hospitals or private practices

| Parameter | University hospital | Private practice | P value* |
|-----------|---------------------|-----------------|----------|
| Number of cases | 108 | 166 |          |
| Duration of clinical signs, n (%) |                      |                 |          |
| <7 days | 49 (45) | 49 (30) | 0.03 |
| >7 days | 34 (31) | 15 (9) |          |
| Unknown | 25 (23) | 102 (61) |          |
| Minimal work-up, n (%)† |                      |                 |          |
| Yes | 75 (69) | 1 (0.6) | <0.001 |
| Broncho-alveolar lavage and culture, n (%) |                      |                 |          |
| Yes | 8 (7) | 2 (1) | 0.007 |
| Cases judged severe, n (%)‡ |                      |                 |          |
| Yes | 25 (24) | 1 (0.6) | 0.7 |
| No | 3 (3) | 0 (0) |          |
| Impossible to judge | 80 (73) | 165 (99.4) |          |
| Diagnosis based on clinical signs in addition to, n (%) | | | |
| Hospitalisation, n (%) |                      |                 |          |
| Yes | 69 (54) | 1 (0.6) | <0.001 |
| No | 39 (30) | 165 (99.4) |          |
| Pretreated, n (%) |                      |                 |          |
| Yes | 41 (37) | 7 (4) | <0.001 |
| No | 66 (62) | 158 (95.4) |          |
| Unknown | 1 (1) | 1 (0.6) |          |
| Antibiotic therapy, n (%) |                      |                 |          |
| Yes | 82 (76) | 89 (49) | <0.001 |
| No | 26 (24) | 77 (51) |          |
| Antibiotic classes, n (%) |                      |                 |          |
| Potentiated aminopenicillins | 59 (71) | 58 (65) | 0.3 |
| Tetracyclines | 12 (15) | 26 (29) | 0.03 |
| Non-potentiated aminopenicillins | 2 (2) | 33 (37) | <0.001 |
| Fluoroquinolones | 23 (28) | 4 (4) | <0.001 |
| First-generation cephalosporins | 4 (5) | 0 (0) | <0.001 |
| Third-generation cephalosporins | 1 (1) | 3 (3) | 0.4 |
| Combination therapy, n (%) |                      |                 |          |
| Yes | 18 (22) | 4 (5) | <0.001 |
| No | 64 (88) | 85 (95) |          |

Continued
(0.1 per cent) were diagnosed with pneumonia based on consistent radiographic changes, 3 dogs (0.1 per cent) with eosinophilic bronchopathy and 1 dog (0.03 per cent) with distemper. The remaining cases (183 dogs, 67 per cent) were classified as ‘unknown’ in the absence of a definitive diagnosis. Those cases were more frequently seen at private practices (150/183; P<0.001).

Agreement with consensus guidelines could be evaluated in 82 per cent (226/274) of dogs with RTI. Of all dogs for which a justification score could be given, 132 cases (58 per cent) were managed according to the guidelines (JS-1). There were significantly more cases with a justification score JS-1 among the university hospitals than private practices (63 per cent vs 39 per cent; P<0.001). A total of 93 (42 per cent) cases were not treated in agreement with the guidelines for prudent antimicrobial prescription (JS-2; 3, 1 per cent; JS-3: 26, 13 per cent; JS-4: 64, 28 per cent). The dogs with a JS-4 score were either treated when not needed (62/64; 97 per cent) or not treated when needed (2/64; 3 per cent).

**Antibiotic prescription for abscesses and bite wounds (WI)**

Numbers and proportions of diagnostic procedures, antimicrobial prescriptions and justification scores are shown in table 8. Of the 175 dogs treated for abscesses or bite wounds at private practices, 157 (90 per cent) received monotherapy or combination antimicrobial therapy.

Forty per cent of dogs presented for abscess (16/40) had at least one clinical sign listed in the guidelines (fever, lethargy, severely contaminated wound or proximity to fragile tissues) justifying systemic antimicrobial treatment. Thirty per cent of those presented for bite wounds had at least one clinical sign listed in the guidelines (bite wound penetrating the epidermis), justifying antimicrobial use. Data were not enough for a judgement in 10 cases (6 per cent). A total of 105 cases (64 per cent) were treated in complete accordance with guidelines (JS-1), whereas 60 (36 per cent) were not (JS-2: 26, 16 per cent; JS-3: 6, 4 per cent; JS-4: 28, 17 per cent). The dogs

| Parameter | University hospital | Private practice | P value* |
|-----------|---------------------|------------------|---------|
| HPCIA§ | Yes | 25 (30) | 7 (8) | <0.001 |
| No | 57 (70) | 82 (92) | |
| Duration of therapy (days) | Median (IQR) | 12.7 (3–20) | 6.3 (0–10) | <0.001 |
| Justification score, n (%) | 1 | 68 (63) | 64 (39) | <0.001 |
| 2 | 1 (1) | 3 (2) | 0.6 |
| 3 | 15 (14) | 11 (7) | 0.04 |
| 4 | 19 (18) | 45 (27) | 0.06 |
| Judgement not possible | 5 (5) | 43 (26) | <0.001 |

*Statistically significant P values after Bonferroni correction are written in bold characters.
†Minimal work-up consist of a thoracic radiograph and CBC.
‡Cases were judged as severe if there was a reduced general state+signs of SIRS (systemic inflammatory response syndrome)/sepsis/left-shift+pulmonary involvement (radiographs or auscultation).
§HPCIA: highest priority critically important antimicrobials include third-generation or higher generation cephalosporins, quinolones, macrolides, ketolides, glycopeptides and polymyxins.
BAL, broncho-alveolar lavage; CBC, complete blood count.

**Table 7** Continued

**Table 8** Presence of clinical signs and antibiotic prescription in 175 dogs with wound infections presented to private practices

| Parameter | Private practice, n (%) |
|-----------|-------------------------|
| Number of cases | 175 |
| Type of lesion | |
| Abscess | 40 (23) |
| Bite | 135 (77) |
| Local wound treatment | |
| Yes | 113 (65) |
| No | 14 (8) |
| Unknown | 48 (27) |
| Drain placed | |
| Yes | 14 (8) |
| No | 161 (92) |
| Antibiotic therapy | |
| Yes | 157 (90) |
| No | 18 (10) |
| Antibiotic classes | |
| Potentiated aminopenicillins | 132 (75) |
| Non-potentiated aminopenicillins | 54 (31) |
| First-generation cephalosporins | 18 (10) |
| Fluoroquinolones | 5 (3) |
| Third-generation cephalosporins | 2 (1) |
| Lincosamide | 1 (0.5) |
| Penicillins | 0 (0) |
| Combination therapy | |
| Yes | 3 (2) |
| HPCIA* | |
| Yes | 7 (4) |
| Duration of therapy: days (IQR) | 7.6 (5.9–10) |
| Justification score | |
| 1 | 105 (60) |
| 2 | 26 (15) |
| 3 | 6 (3) |
| 4 | 28 (16) |
| Judgement not possible | 10 (6) |

*HPCIA: highest priority critically important antimicrobials include third-generation or higher generation cephalosporins, quinolones, macrolides, ketolides, glycopeptides and polymyxins.
with a JS-4 score were either treated when not needed (15/28; 54 per cent) or not treated when needed (13/28; 46 per cent). Dogs not treated when needed were in the vast majority (12/13) dogs with bite wounds.

**DISCUSSION**

The results of this study demonstrate that there is ample room for improvement regarding the prudent use of antimicrobials in Switzerland, as inappropriate prescriptions were common for dogs with AD, UTI, RTI and WI. Indeed, in 41 per cent of cases, antimicrobial treatment was in partial or complete disagreement with national and international guidelines. These findings concur with studies in human and veterinary medicine showing that antimicrobials are commonly prescribed without clear indication. Moreover, expertise of treatment after minimal diagnostic work-up has been diagnostics. However, owner expectations for antimicrobial rationals, which may be characterised by more complex bials. All these factors are consistent with a referral popu-

 severity disease and received a combination of antimicro-

 bials in dogs with AD. Metronidazole and fenbendazole

 are commonly used for the treatment of clinical or labo-

 ratory signs consistent with sepsis, but in this cohort, the use of antimicrobials was not significantly associated with the presence of sepsis. Instead the use of antimicrobials was clearly associated with a higher risk of bacterial translocation and therefore requires antimicrobial treatment. Recent evidence however does not support this concept, as dogs with acute haemorrhagic diarrhea syndrome (AHDS) were no more likely to have positive blood cultures than healthy controls. Furthermore, in a prospective placebo controlled clinical trial in a population of 60 dogs with AHDS, there were no significant differences between the group of dogs receiving intravenous amoxicillin-clavulanic acid and controls regarding the number of hospitalisation days, clinical score and outcome. The use of antimicrobials should therefore be reserved for AD patients with clinical signs of sepsis.

Metronidazole was the most commonly used antimicrobial in dogs with AD. Metronidazole and fenbendazole have been used interchangeably in the past to treat clinical giardiasis and might have been the reason for prescription of metronidazole in some of the dogs even though fenbendazole is now the recommended first-line treatment. Metronidazole is commonly used by small animals practitioners, as it is believed to reduce the duration of clinical signs and the severity of diarrhoea, although evidence is lacking. While nitroimidazoles are not classified as critically important antimicrobials in Switzerland, their use to treat AD should nevertheless be restricted. Metronidazole is used in human medicine.
for the treatment of often life-threatening \textit{Clostridium} infections, and the number of metronidazole-resistant bacterial isolates from animals and humans is rising.\footnote{50} Metronidazole may increase the risk of selection of multidrug resistant \textit{E.coli}\footnote{18,31} and possibly favours bacterial translocation.\footnote{32} Finally, metronidazole can cause a potentially severe neurotoxicity in dogs,\footnote{53-55} as well in humans\footnote{56-59} and should therefore be used cautiously.

Minimal diagnostic work-up was limited to CBC in the group of AD, as the presence of neutropenia, neutrophilia and/or a left-shift are important sepsis criteria.\footnote{31} Parasitological examination of faeces was not included in the minimal diagnostic work-up, as it was commonly replaced by the use of broad-spectrum antiparasitic treatments. Faecal culture and PCR for specific pathogens such as \textit{Campylobacter} spp or \textit{Clostridia} spp were also not considered core elements of the work-up, because there is not a clear link between the presence of these pathogens in the gut and the occurrence of diarrhoea in dogs.\footnote{60-62}

In the group of dogs with UTI, 88 per cent of dogs received antimicrobial treatments, even though a bacterial aetiology was confirmed in only 36 per cent of cases, either via sediment analysis or culture. This is consistent with results of other national studies.\footnote{13-65} It is very common for patients of first opinion practices with acute signs of lower urinary tract disease to receive empirical antimicrobial treatment without prior urinalysis and/or culture. In a previous questionnaire-based study, only 32.5 per cent of companion animal practitioners in Europe reported that they frequently undertake antimicrobial susceptibility testing when prescribing antimicrobials, whereas 9.1 per cent never requested such tests.\footnote{41} Similarly, in a US study, only 38 per cent of dogs with suspicion of UTI receiving antimicrobials had a definitive diagnosis of bacterial infection.\footnote{10} While in dogs with lower urinary tract signs, bacterial UTIs are more common than in cats, the presence of bacteria should nevertheless be confirmed via sediment analysis and/or culture before starting antimicrobial therapy.\footnote{28,30} This is emphasised by the fact that around 50 per cent of urine samples of dogs with clinical signs of UTI are sterile on culture.\footnote{53,64}

Similar to previous studies,\footnote{10,17,63} potentiated aminopenicillins were used more commonly than non-potentiated aminopenicillins to treat sporadic UTI in this cohort, although non-potentiated aminopenicillins are the recommended choice.\footnote{26,30} The use of non-potentiated aminopenicillins is preferred whenever possible, because the addition of clavulanic acid increases AmpC-mediated resistance to first-generation, second-generation and third-generation cephalosporins.\footnote{65,66} Fluoroquinolones were the second most commonly used antimicrobials, and their use was associated with, but not restricted to, non-castrated males. The use of antimicrobials with good penetration of the prostate such as fluoroquinolones and potentiated sulphonamides has been recommended for any UTI in uncastrated dogs in the past.\footnote{55} Potentiated sulphonamides were only rarely used in this cohort. Besides potential unwanted adverse effects such as keratoconjunctivitis sicca or hepatitis,\footnote{57,68} the rare use of potentiated sulphonamides in this study could be due to the limited availability of this class of drugs for companion animals in Switzerland.\footnote{69} The new guidelines for management of UTI issued by the International Society for Companion Animal Infectious Diseases recommend that the prostate has to be evaluated in non-castrated males with UTI. In the absence of evidence of prostatic involvement, it is recommended to treat UTI in non-castrated males as a sporadic UTI.\footnote{30}

The vast majority of dogs with suspicion of UTI that were not treated in accordance with the guidelines were dogs, which received antimicrobial therapy in the absence of bacteriuria on sediment analysis or culture. The reasons for non-adherence were commonly not clear from the medical records. It is imaginable that treatments were started empirically and not discontinued when the sediment or culture result was received or that clinicians disbelieved the results of the sediment analysis but did not follow up with culture.

The tendency to selectively gather and interpret evidence that confirms a suspected diagnosis but ignore the evidences that might disconfirm it (confirmation bias) and risk avoidance have been previously discussed important elements, which may lead to incoherence between diagnostic test results and clinical decision making in patients with UTI.\footnote{65} Withholding antimicrobial therapy, while providing analgesic treatment, in patients, which can tolerate this approach until a confirmatory test result is received, may reduce the number of unnecessary treatments of UTI.\footnote{65}

The group of RTI was diverse and included dogs with kennel cough, aspiration pneumonia and bronchopneumonia. While kennel cough is often a purely clinical diagnosis, a diagnosis of aspiration pneumonia is based on a consistent history and radiographic pattern, whereas a diagnosis of bronchopneumonia should be confirmed via cytological and cultural examination of a BAL sample.\footnote{76} However, in this cohort, 58 per cent dogs were treated on a clinical suspicion of an RTI, and no further diagnostic tests were recorded.

At university hospitals, 54 per cent of RTI cases were hospitalised and in 24 per cent, the clinical signs were judged severe. While this could explain the significantly more frequent use of combination therapy and fluoroquinolones, it could also give an indication to why relatively few bronchosopies and/or BAL procedures were performed. Indeed, critically ill patients might not be stable enough to undergo general anaesthesia, which is required for bronchoscopy and/or BAL, and tracheal washes, which do not require general anaesthesia, are rarely performed. The use of BAL and antimicrobial susceptibility testing is however crucial to select the most appropriate antimicrobial. A recent study describing sensitivity patterns of bacterial isolates from BAL showed that less than 35 per cent of \textit{Pseudomonas} specie and less than 50 per cent of \textit{E.coli} were susceptible to beta-lactam antimicrobials, potentiated
sulfonamides or doxycycline, which are commonly used to treat canine lower respiratory tract infections.

While guidelines recommend the use of fluoroquinolones only for severe cases of pneumonia with susceptible organisms, combination therapy using aminopenicillins and fluoroquinolones were commonly used as first-line treatment in the absence of signs of sepsis in this cohort, most likely as a consequence of risk avoidance. In cases with kennel cough, aminopenicillins were commonly prescribed, even though most cases of kennel cough are self-limiting and do not require antimicrobial treatment. If kennel cough is associated with a poor general condition, fever or signs of lower airway involvement, doxycycline is recommended as first-line empirical treatment. Doxycycline is well tolerated by dogs and has good in vitro activity against canine isolates of *Bordetella bronchiseptica*.

As treatments of uncomplicated wounds and abscesses are rare in referral practice, this indication was only assessed in private practices. In this study, 90 per cent of the dogs presented for absorb or bites were treated with antimicrobials, which corresponds to results of other studies, where the rate of antimicrobial prescription for abscesses and bite wounds was between 90 per cent and 97 per cent. According to guidelines, drainage of abscesses is the most important treatment, and antimicrobials are indicated for bite wounds penetrating the epidermis and for abscesses only in case of fever, reduced general status, highly contaminated wounds or proximity to fragile tissues. However, in this cohort, 90 per cent of dogs with abscesses received antimicrobials, while only 39 per cent had an indication. These data, therefore, indicate a large potential for reduction of antimicrobial prescriptions for this indication.

Contrary to other indications, about half of the cases in disagreement with guidelines for WI were because of the non-prescription of antimicrobial although needed. This is in contrast with results from cats in Switzerland and other studies.

The limitations of the present study include its retrospective nature and the commonly incomplete documentation of cases in the databases, particularly in private practices, where information regarding history and clinical signs was often not recorded. In this study, practices were only able to participate if they were exclusively using practice management software for their medical record keeping. While vets in Switzerland are obliged to keep medical records, the information was sometimes patchy and difficult to interpret. Moreover, a selection bias could be present. The enrolment of private practices was voluntary, and clinics willing to participate may already be using antimicrobials more prudently leading to an overestimation of the overall adherence to guidelines in the country. Furthermore, the manual review of retrospective data by the two evaluators (CL and KS) possibly leaves a margin of error and judgement errors cannot be ruled out.

Finally, antimicrobial prescriptions were only assessed for four conditions. One important indication for antimicrobial prescription in small animal medicine is pyoderma. Given that overuse of systemic antimicrobials is common for this condition it should be included in future studies.

In conclusion, in 2016, antimicrobial prescription for selected canine diseases showed a poor agreement with national and international guidelines, both at university hospitals and private practices. Antimicrobial stewardship measures are clearly needed to improve prudent use. The impact of the ASP online tool AntibioticScout. ch on prescribing habits of Swiss veterinarians will be assessed in a follow-up study.

**Author affiliations**

1Department Clinical Veterinary Medicine, Division Small Animal Internal Medicine, Vetsuisse Faculty University of Bern, Bern, Switzerland
2Clinic for Small Animal Internal Medicine, Vetsuisse Faculty University of Zurich, Zurich, Switzerland
3Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
4Division of Pharmacology and Toxicology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
5Institute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty University of Zurich, Zurich, Switzerland

**Acknowledgements** The work was performed as a collaboration between the Division of Small Animal Internal Medicine, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of Bern, Switzerland, the Clinic of Small Animal Internal Medicine and the Institute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. The authors gratefully acknowledge the veterinarians of the Clinics for Small Animal Internal Medicine in Bern and Zurich, as well as the private practices for their contribution of cases.

**Funding** This research was supported by Swiss National Science Foundation (NRP72 project 407240_167054).

**Competing interests** None declared.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/).

**ORCID iDs**

Kira Schmitt [http://orcid.org/0000-0002-5790-3636](http://orcid.org/0000-0002-5790-3636)
Simone Schuller [http://orcid.org/0000-0002-7316-4423](http://orcid.org/0000-0002-7316-4423)

**REFERENCES**

1. Blair JMA, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance. *Nat Rev Microbiol* 2015;13:42–51.
2. Grönhall T, Moodley A, Nykäsenoja S, et al. Large outbreak caused by meticillin resistant *Staphylococcus pseudintemedius* ST71 in a Finnish Veterinary Teaching Hospital—from outbreak control to outbreak prevention. *PLoS One* 2014;9:e110084.
3. Grönlund Andersson U, Wallensten A, Haagman S, et al. Outbreaks of meticillin-resistant *Staphylococcus aureus* among staff and dogs in Swedish small animal hospitals. *Scand J Infect Dis* 2014;46:310–4.
4. Huber H, Zweifel C, Wittenbrink MM, et al. ESBL-producing uropathogenic Escherichia coli isolated from dogs and cats in Switzerland. *Vet Microbiol* 2013;162:992–6.
5. Ewers C, Bethe A, Semmler T, et al. Extended-Spectrum *β*-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective. *Clin Microbiol Infect* 2012;18:646–55.
6 Feiring E, Walter AB. Antimicrobial stewardship: a qualitative study of the development of national guidelines for antibiotic use in hospitals. BMC Health Serv Res 2017;17:747.

7 Swedish Veterinary Association. Guidelines for the clinical use of antibiotics in the treatment of dogs and cats (Antibiotikapolitik för Hund- och Kattsjukvård). Vol. 2. Sweden: SSVS, 2009.

8 Jessen LR, Damborg P, Spohr A. Antibiotic use guidelines for companion animal practice (Antibiotikavejledning til fælledyr). Vol. 1. Dan Dansk Dyregeforenings Sektion for Hund, 2012.

9 Hardefeldt LY, Crabb HK, Bailey KE, et al. Appraisal of the Australian veterinary prescribing guidelines for antimicrobial prophylaxis for surgery in dogs and cats. Aust Vet J 2019;97:316–22.

10 Wayne A, McCarthy R, Lindemayer J. Therapeutic antibiotic use patterns in dogs: observations from a veterinary teaching hospital. J Small Anim Pract 2011;52:310–8.

11 Hardefeldt LY, Holloway S, Trott DJ, et al. Antimicrobial prescribing in dogs and cats in Australia: results of the Australasian infectious disease Advisory panel survey. J Vet Intern Med 2017;31:1100–7.

12 Van Cleven A, Sarrazin S, de Rooster H, et al. Antimicrobial prescribing behaviour in dogs and cats by Belgian veterinarians. Vet Rec 2018;182:324.

13 Buckland EL, O’Neill D, Summers J, et al. Characterisation of antimicrobial usage in cats and dogs attending UK primary care companion animal veterinary practices. Vet Rec 2016;178:488–89.

14 Hölsö K, Rantalä M, Lillas A, et al. Prescribing antimicrobial agents for dogs and cats via university pharmacies in Finland—patterns and quality of information. Acta Vet Scand 2005;46:87–93.

15 Jessen LR, Sørensen TM, Lilja ZL, et al. Cross-Sectional survey on the use and impact of the Danish national antibiotic use guidelines for companion animal practice. Acta Vet Scand 2017;59:81.

16 Barbarossa A, Rambaldi J, Miraglia V, et al. Survey on antimicrobial prescribing patterns in small animal veterinary practice in Emilia Romagna, Italy. Vet Rec 2017;181:69.

17 Weese JS, Investigation of antimicrobial use and the impact of antimicrobial use guidelines in a small animal veterinary teaching hospital: 1995-2004. J Am Vet Med Assoc 2006;228:553–8.

18 Singleton DA, Sánchez- Vizcaíno F, Dawson S, et al. Patterns of antimicrobial agent prescription in a sentinel population of canine and feline veterinary practices in the United Kingdom. Vet J 2017;224:18–24.

19 Sarrazin S, Vandael F, Cleven V, et al. The impact of antimicrobial use guidelines on prescription habits in fourteen Flemish small animal practices. Vlaams Diergeneeskundig Tijdschrift 2017;86:173–82.

20 Regula G, Torniani K, Gassner B, et al. Prescription patterns of antimicrobials in veterinary practices in Switzerland. J Antimicrob Chemother 2009;63:805–11.

21 Escher M, Vanni M, Intorre L, et al. Characterisation of antimicrobial use in companion animals in Italy: a retrospective study in a veterinary teaching hospital in Italy. J Antimicrob Chemother 2011;66:920–7.

22 Radford AD, Noble PJ, Coyne KP, et al. Antibacterial prescribing patterns in small animal veterinary practice identified via SAVSNET: the small animal veterinary surveillance network. Vet Rec 2011;169:310.

23 Hardefeldt LY, Selinger J, Stevenson MA, et al. Population wide assessment of antimicrobial use in dogs and cats using a novel data source - A cohort study using pet insurance data. Vet Microbiol 2018;225:34–9.

24 Schmitt K, Lehner C, Schuller S, et al. Antimicrobial use for selected diseases in cats in Switzerland. BMC Vet Res 2019;15:94.

25 European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe – annual report of the European antimicrobial resistance surveillance network (EARS-Net) 2017. Stockholm: ECDC, 2018.

26 Peter R, Müntener C, Demuth D, et al. [Antibiogramme: Online tool for antimicrobial stewardship in veterinary medicine]. Schweiz Arch Tierheilkd 2016;158:805–10.

27 Peter R, Demuth D, Müntener C, et al. [Antibiogramme: Online tool for antimicrobial stewardship in veterinary medicine]. Schweiz Arch Tierheilkd 2017;159:525–33.

28 Weese JS, Blondeau JM, Boothe D, et al. Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines Working group of the International Society for companion animal infectious diseases. Vet Med Int 2011;2011:1–9.

29 Identititas AG, Empriente, 2018. Available: https://tierstatistik. identititas.ch/fr/dog [Accessed 30 Oct 2019].

30 Weese JS, Brooks SW, Boothe D, et al. International Society for companion animal infectious diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats. Vet J 2019;247:8–25.

31 Hauptman JG, Walshaw R, Olivier NB. Evaluation of the sensitivity and specificity of diagnostic criteria for sepsis in dogs. Vet Surg 1997;26:393–7.

32 Collignon PJ, Conly JM, Andremont A, et al. World Health Organization ranking of antimicrobials according to their importance in human medicine: a critical step for developing risk management strategies to control antimicrobial resistance from food animal production. Clin Infect Dis 2016;63:1087–93.

33 DePestel DD, Eiland EH, Lusardi K, et al. Assessing appropriateness of antimicrobial therapy: in the eye of the interpreter. Clin Infect Dis 2014;59(Suppl 3):S154–61.

34 Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA 2016;315:1864–73.

35 Chipangura JK, Eager H, Koqoe M, et al. An investigation of antimicrobial usage patterns by small animal veterinarians in South Africa. Prev Vet Med 2017;136:29–38.

36 Jacob ME, Hoppin JA, Steers N, et al. Opinions of clinical veterinarians at a US veterinary teaching hospital regarding antimicrobial use and antimicrobial-resistant infections. J Am Vet Med Assoc 2015;247:938–44.

37 Rantala M, Hölsö K, Lilja ZL, et al. Survey of condition-based prescribing of antimicrobial drugs for dogs at a veterinary teaching hospital. Vet Rec 2004;155:259–62.

38 Hughes LA, Williams N, Clegg P, et al. Cross-sectional survey of antimicrobial prescribing patterns in UK small animal veterinary practice. Prev Vet Med 2012;104:309–16.

39 King C, Smith M, Currie K, et al. Exploring the behavioural drivers of veterinary surgeon antibiotic prescribing: a qualitative study of companion animal veterinary surgeons in the UK. BMC Vet Res 2018;14:332.

40 Hopman NEM, Hulscher MEJL, Graveland H, et al. Factors influencing antimicrobial prescribing by Dutch companion animal veterinarians: a qualitative study. Prev Vet Med 2018;158:106–13.

41 De Bruijne N, Atkinson J, Hladoulová L, et al. Factors influencing antibiotic prescribing habits and use of sensitivity testing amongst veterinarians in Europe. Vet Rec 2013;173:475–75.

42 Currie K, King C, Nuttall T, et al. Expert consensus regarding drivers of antimicrobial stewardship in companion animal veterinary practice: a Delphi study. Vet Rec 2018;182:691.

43 Federal Office of Public Health and Federal Food Safety and Veterinary Office. Swiss antibiotic resistance report 2018. usage of antibiotics and occurrence of antibiotic resistance in bacteria from humans and animals in Switzerland. 2018. FOPH publication number 2018-OEG.

44 Gómez-Poveda B, Moreno MA. Antimicrobial prescriptions for dogs in the capital of Spain. Front Vet Sci 2018;5:309.

45 Mateus A, Brodbelt DC, Barber N, et al. Antimicrobial usage in dogs and cats in first opinion veterinary practices in the UK. J Small Anim Pract 2011;52:515–21.

46 Jones PH, Dawson S, Gaskell RM, et al. Surveillance of diarrhoea in small animal practice through the small animal veterinary surveillance network (SAVSNET). Vet J 2018;204:183–91.

47 Stephen J, Ettinger ECF. Disease of the Small Intestine. In: Textbook of veterinary internal medicine. 6th edn. Elsevier, 2006.

48 Unterer S, Lechner E, Mueller RS, et al. Prospective study of bacteremia in acute haemorrhagic diarrhoea syndrome in dogs. Vet Rec 2015;176:309.

49 Unterer S, Strohmeyer K, Kruse BD, et al. Treatment of aseptic dogs with hemorrhagic gastroenteritis with amoxicillin-clavulanic acid: a prospective blinded study. J Vet Intern Med 2011;25:973–9.

50 Spigaglia P. Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther Adv Infect Dis 2016;3:23–42.

51 Gibson JS, Morton JM, Cobbold RN, et al. Risk factors for dogs becoming rectal carriers of multidrug-resistant Escherichia coli during hospitalization. Epidemiol Infect 2011;139:1511–21.

52 Wells CL, Maddaus MA, Reynolds CM, et al. Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria. Infect Immun 1987;55:2689–94.

53 Ortiz V, Klein L, Channell S, et al. Evaluating the effect of metronidazole plus metronidazole plus amoxicillin-clavulanate versus amoxicillin-clavulanate alone in canine haemorrhagic diarrhoea: a randomised controlled trial in primary care practice. J Small Anim Pract 2018;59:398–403.

54 Evans J, Levesque D, Knowles K, et al. Diazepam as a treatment for neurotoxicity in 26 dogs. J Vet Intern Med 2019;33:1067–76.

55 Tauro A, Beltran E, Cherubini GB, et al. Metronidazole-induced neurotoxicity in 26 dogs. Aust Vet J 2018;96:495–501.
56 Neufeld NH, Mohamed NS, Grujich N, et al. Acute neuropsychiatric symptoms associated with antibiotic treatment of Helicobacter pylori infections: a review. J Psychiatr Pract 2017;23:25–35.

57 Hernández Ceruelos A, Romero-Quezada LC, Ruvalcaba Ledezma JC, et al. Therapeutic uses of metronidazole and its side effects: an update. Eur Rev Med Pharmacol Sci 2019;23:397–401.

58 Yazdani RM, Kayfan S, Cao J, et al. MRI findings of metronidazole neurotoxicity in a pediatric patient with chronic diarrhea. Radiol Case Rep 2019;14:75–8.

59 Singh R, Kaur R, Pokhariyal P, et al. Sequential MR imaging (with diffusion-weighted imaging) changes in metronidazole-induced encephalopathy. Indian J Radiol Imaging 2017;27:129–32.

60 Goldstein MR, Kruth SA, Bersenas AME, et al. Detection and characterization of Clostridium perfringens in the feces of healthy and diarrheic dogs. Can J Vet Res 2012;76:161–5.

61 Stavisky J, Radford AD, Gaskell R, et al. A case-control study of pathogen and lifestyle risk factors for diarrhoea in dogs. Prev Vet Med 2011;99:185–92.

62 Marks SL, Kather EJ, Kass PH, et al. Genotypic and phenotypic characterization of Clostridium perfringens and Clostridium difficile in diarrheic and healthy dogs. J Vet Intern Med 2002;16:533–40.

63 Sørensen TM, Bjørnvad CR, Cordoba G, et al. Effects of diagnostic work-up on medical decision-making for canine urinary tract infection: an observational study in Danish small animal practices. J Vet Intern Med 2018;32:743–51.

64 Çetin C, Şentürk S, Kocabiyik A, et al. Bacteriological examination of urine samples from dogs with symptoms of urinary tract infection. Turk J Vet Anim Sci 2003;27:1225–9.

65 Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009;22:161–82. Table of Contents.

66 Kitiz MD, Ferre B, Coutrot A, et al. In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria. Eur J Clin Microbiol Infect Dis 1989;8:783–8.

67 Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther 2004;27:129–38.

68 Trepanier LA, Danhof R, Toll J, et al. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. J Vet Intern Med 2003;17:647–52.

69 ClinPharm/CliniTox. Soffclass Sulfonamides [Internet]. Available: https://www.vetpharm.uzh.ch/perldocs/index_t.htm [Accessed 16 Jun 2019].

70 Lappin MR, Blondeau J, Boothe D, et al. Antimicrobial use guidelines for treatment of respiratory tract disease in dogs and cats: antimicrobial guidelines Working group of the International Society for companion animal infectious diseases. J Vet Intern Med 2017;31:279–94.

71 Rheinwald M, Hartmann K, Hähner M, et al. Antibiotic susceptibility of bacterial isolates from 502 dogs with respiratory signs. Vet Rec 2015;176:357–5.

72 Weese JS, Giguère S, Guardabassi L, et al. ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance. J Vet Intern Med 2015;29:487–98.

73 Johnson LR, Queen EV, Vernau W, et al. Microbiologic and cytologic assessment of bronchoalveolar lavage fluid from dogs with lower respiratory tract infection: 105 cases (2001-2011). J Vet Intern Med 2013;27:259–67.

74 Poncet C. Fiches de recommandations pour un bon usage des antibiotiques. In: Guide de bonnes pratiques. France: AFVAC, 2006: 23–4.

75 Holloway S, Trott D, Shipstone M. AIDAP antibiotic prescribing detailed guidelines. Zoetis, 2013.